Calcitonin nasal spray in patients with chronic asthma: a double-blind crossover study vs placebo.
The study, which was of a double-blind, crossover type vs placebo in 12 subjects suffering from postmenopausal osteoporosis and chronic asthma, evaluates the effects of acute, prolonged administration of salmon calcitonin (sCT) nasal spray on respiratory function (FEV1, MMEF, V25). No significant changes in bronchomotor tone were observed as a result of prolonged treatment with sCT nasal spray, thereby confirming the complete tolerability of the formulation.
Dal Negro
R
R
Department of Clinical Respiratory Physiology, Bussolengo General Hospital, Verona, Italy.
Turco
P
P
Pomari
C
C
Trevisan
F
F
D000281:Administration, Intranasal; D000328:Adult; D000336:Aerosols; D000368:Aged; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D002116:Calcitonin / Q000008:administration & dosage / Q000627:therapeutic use*; D002908:Chronic Disease; D004311:Double-Blind Method; D005541:Forced Expiratory Volume; D006801:Humans; D008297:Male; D008448:Maximal Expiratory Flow Rate; D008875:Middle Aged; D014797:Vital Capacity
D000336:Aerosols; D002116:Calcitonin